Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CSL

- PMLiVE

EU clears AZ’s FDA-rejected diabetes combination

Approval of two-drug therapy Qtern presents first-to-market advantage in Europe

- PMLiVE

Celgene’s Revlimid cleared for aggressive lymphoma type in EU

Analysts anticipate sales of up to $10bn for the newly-expanded drug in coming years

EU flag

EC approves Bial’s Parkinson’s disease therapy

Ongentys will be given a phase roll-out in 2016 and 2017

- PMLiVE

Amgen’s Kyprolis wins new indication in Europe

Regulators have handed the treatment a less restrictive licence in multiple myeloma 

- PMLiVE

AZ gets EU green light for new antibiotic Zavicefta

EMA approves combination drug for treatment of multidrug resistant infections

Gilead Sciences

Gilead gets EU nod for TAF-based triple therapy for HIV

Once-daily, single-tablet Odefsey reduces risks of side effects such as renal and bone toxicity

Roche Basel Switzerland

Roche’s Gazyvaro cleared for follicular lymphoma in Europe

Second indication anticipated to increase peak sales by up to $1bn

Roche Basel Switzerland

Roche gets EU okay for Avastin/Tarceva combination

Lung cancer therapy ‘significantly’ extends progression-free survival

EU flag

Imbruvica wins wider European leukaemia licence

AbbVie and J&J’s first-in-class drug now approved to treat all CLL patients in the EU

EU flag

Second Remicade biosimilar given green light in Europe

Samsung Bioepis’ Flixabi provides another lower-cost treatment option

- PMLiVE

J&J gets European OK for myeloma therapy Darzalex

First-in-class immunotherapy achieved ‘significant increase’ in overall survival

eHealth set to benefit from EC’s ‘single digital market’

Says will help European industry, researchers and public authorities

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links